Edward Nash
Stock Analyst at Canaccord Genuity
(3.70)
# 485
Out of 5,124 analysts
77
Total ratings
45.71%
Success rate
9.99%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Maintains: Buy | $140 → $99 | $35.78 | +176.69% | 11 | Jan 2, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.33 | +972.96% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $558.01 | +5.20% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $32.30 | +231.27% | 2 | Nov 12, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $14 → $16 | $10.05 | +59.20% | 7 | Nov 7, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $5.46 | +412.82% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $4.54 | +340.53% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $26.28 | +135.92% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $35.80 | +31.28% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.38 | +552.17% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.28 | +212.50% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $78.25 | +13.74% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.00 | +700.00% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $1.91 | +790.05% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.07 | -34.85% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.82 | +21,789.82% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.27 | +406.33% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $22.54 | +263.80% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $22.31 | +115.15% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.16 | +12,496.90% | 1 | Nov 8, 2017 |
Corcept Therapeutics
Jan 2, 2026
Maintains: Buy
Price Target: $140 → $99
Current: $35.78
Upside: +176.69%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.33
Upside: +972.96%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $558.01
Upside: +5.20%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $32.30
Upside: +231.27%
Ventyx Biosciences
Nov 7, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $10.05
Upside: +59.20%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $5.46
Upside: +412.82%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $4.54
Upside: +340.53%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $26.28
Upside: +135.92%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $35.80
Upside: +31.28%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.38
Upside: +552.17%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.28
Upside: +212.50%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $78.25
Upside: +13.74%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.00
Upside: +700.00%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $1.91
Upside: +790.05%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.07
Upside: -34.85%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.82
Upside: +21,789.82%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.27
Upside: +406.33%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $22.54
Upside: +263.80%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $22.31
Upside: +115.15%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.16
Upside: +12,496.90%